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rubles ($209) per extra patient without moderate and severe dis-
ability after 3 months of treatment. CONCLUSION: Betahistine
is an appropriate alternative to cinnarizine for patients with
vertigo.
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OBJECTIVE: To assess the cost-effectiveness of switching from
oral polio vaccine (OPV) to inactivated poliovirus vaccine (IPV),
or to cease polio vaccination in routine immunization services in
South Africa. METHODS: The incremental cost-effectiveness of
three different polio vaccination alternatives was compared to
the current schedule of six doses of OPV: (1) IPV at 2, 4, and 6
months; (2) IPV at 6, 10, 14 weeks and 18 months and (3) ces-
sation of polio vaccination. The costs of introducing IPV in a
separate vial as well as in different combination vaccines were
estimated. Assumptions about IPV vaccine prices were based on
indications from vaccine manufacturers. Treatment costs of polio
and the costs of lost productivity were included. The health
impact of OPV cessation was measured in terms of Vaccine Asso-
ciated Paralytic Paralysis [VAPP] cases and Disability Adjusted
Life Years [DALYs] averted. One-way sensitivity analysis was
performed on the most uncertain variables. RESULTS: The use
of OPV in routine immunization services is projected to result in
2.96 VAPP cases in the 2005 cohort. A switch to IPV will
increase the total vaccine budget by at least 20%. The cost-effec-
tiveness of the different IPV alternatives varies between US$
118,000 and US$594,000 per discounted DALY averted. 3 doses
of IPV in a 10-dose vial is the most cost-effective option. CON-
CLUSION: Due to the risk of VAPP, it has been recognized that
when global polio eradication has been achieved, all countries
must cease the use of OPV if the world is to remain polio-free.
However, at the assumed vaccine prices, IPV does not appear to
be cost-effective in the South African situation. The alternative
of ceasing polio vaccination altogether is more economically
acceptable, but the perceived risks of this alternative could be a
hindrance for its implementation.
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OBJECTIVE: In addition to the costs of treatment and preven-
tion, diseases generate other types of costs that are not always
addressed. The purpose of the present work is to identify
measure and evaluate the costs of informal care for neurological
diseases in Spain. METHODS: The data collected in the Survey
on Disabilities, Impairments, and State of Health (EDDES, for
its initials in Spanish) of the National Institute of Statistics (INE)
was used to estimate these costs. The EDDES is a national survey
that covers all individuals residing in primary family housing. A
total of 79,000 households were selected and information
regarding 290,000 people was collected. We estimate that
423,188 people (1.03% of Spanish population in 2001) suffer
an incapacity caused by a neurological disease: stroke, sclerosis,
dementia (including Alzheimer) and Parkinson. Our estimation
includes only those costs that have to do with informal care; that
is, those caregivers that are not paid for their work. We estimated
the opportunity cost of the time of caregivers, distinguishing if
the caregiver has given up his job or has reduced the total supply
of hours of work. RESULTS: The informal costs estimated range
between 2402 and 2926 millions of euros (at year 2002 prices),
depending on how comorbidity is handled. The estimated costs
of informal care of each neurological disease were: stroke (823
to 1007); dementia (1021 to 1246); Parkinson disease (329 to
401); and multiple sclerosis (229 to 272). The estimated infor-
mal costs represent a %6.3 to %7.7 per cent of the total health
care costs of the Spanish National Health System. We also esti-
mated the informal costs per patient and disease. CONCLU-
SIONS: The cost of informal care in main neurological disorders
is substantial, and if ﬁnanced it could devote a considerable
budget from the overall Spanish Health Care System 
expenditure.
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OBJECTIVES: To identify and summarise the economic evidence
for botulinum toxins in post-stroke spasticity and spasticity asso-
ciated with cerebral palsy. METHODS: Cost-effectiveness and
cost-analysis studies of interventions for treatment of postictal
and cerebral-palsy-related spasticity, in which at least one arm
consists of a botulinum toxin, were considered for inclusion in
the review. Medline, Embase, NHSEED and the proprietary
Allergan Botulinum Database were searched up until February
16, 2004 for relevant studies. Additionally, conference proceed-
ings of seven clinical and pharmacoeconomic organisations 
were hand searched for the period of 2001 to 2004. RESULTS:
One cost-effectiveness (Wallesch 1997), two cost-consequence
(Houltram 2001, Loaiza 2000) and two cost studies (Balkrish-
nan 2002, Radensky 2001) met the criteria for inclusion in 
the review. Wallesch presented the incremental cost per unit
improvement in Ashworth scale, Loaiza presented quality
adjusted life years and Houltram presented Modiﬁed Ashworth
Scale together with several other functional measures. The cost
analyses found that overall treatment costs were lower in treat-
ment plans that included botulinum toxin A (Btx-a). Although
Btx-a increased drug costs by between $750 and $1000 annu-
ally, overall treatment costs were lower due to the reduced hos-
pitalisation and nursing facility admissions associated with Btx-a
treatment. Btx-a treatment was also associated with fewer co-
administered treatments, and resulted in lower treatment costs
than treatment plans that did not include Btx-a. CONCLUSION:
The addition of botulinum toxin to a treatment regimen appears
to be cost neutral. There is a need for cost-effectiveness analyses
using outcome measures with greater external validity than those
identiﬁed in the studies included in the review. A cost-utility
analysis based on clearly derived utilities is required.
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